InvestorsHub Logo
Followers 0
Posts 484
Boards Moderated 0
Alias Born 10/10/2014

Re: None

Thursday, 09/21/2017 5:04:09 PM

Thursday, September 21, 2017 5:04:09 PM

Post# of 2099
The failure of VB-201 in psoriasis and ulcerative colitis in phase 2 is now a positive factor for the company, imo. It shows that if a treatment is not working, the company will stop it early. This can be grouped in the positive factors bucket (like facilities, Thai Lee, upcoming OVAL study, etc). They are positive signs that the company is doing the right things but they don't impact the phase 3 GLOBE results.

Until more concrete indications come out from DSMC and FDA, this is all we have for now.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VBLT News